close icon

Honeywell Stock is a Temptation to Resist

Honeywell is a multinational conglomerate specializing in industrial software in the aerospace, home and building, performance materials, safety and productivity solutions technologies segments. The company has been around for over a century. It is a component of the S&P 500 index and just rejoined the DJIA earlier this year.

HON has a market cap of almost $150 billion, over half of which it has gained in the nine months since March. The recovery from the coronavirus crash saw the stock price rise from $101 to nearly $214 a share. Honeywell is now hovering at new all-time highs, which surely tempts many to join the uptrend now. The chart below explains why we think this would be a bad idea.

Honeywell can lose half its value in Elliott Wave correction

The chart above allows us to put Honeywell ‘s entire progress since October 2002 in Elliott Wave context. The impressive uptrend which took the stock price from below $18 to over $213 in eighteen years looks like a textbook impulse pattern. Its five waves are labeled (1)-(2)-(3)-(4)-(5).

Honeywell Is a Great Business, but a Bad Investment at This Price

Wave (2) unfolded during the Financial crisis of 2007-2009, while wave (4) corresponds to the COVID-19 crash. Between these two is wave (3), whose impulsive structure is marked 1-2-3-4-5. The sub-waves of wave 3 of (3) is also visible.

If this count is correct, the sharp surge Honeywell investors have been enjoying over the past nine months must be wave (5). According to the theory, a three-wave correction follows every impulse. This means that once wave (5) ends, we can expect a major retracement to occur.

The negative phase of the wave cycle usually erases the entire fifth wave. In Honeywell’s case, this translates into a decline back to roughly $120-$100 a share. The RSI indicator supports this pessimistic outlook with a bearish divergence between waves (3) and (5). Besides, HON can hardly be expected to grow at a 30% clip to justify its 2020 P/E of 30. In out opinion, there are plenty of technical and fundamental reasons to avoid this otherwise great business.

Similar Elliott Wave setups occur in the Forex, crypto and commodity markets, as well. Our Elliott Wave Video Course can teach you how to uncover them yourself!

Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

DraftKings on the Verge of Another 40% Decline

It’s been almost three and a half months since we examined DraftKings stock in October, 2020. The share price was hovering near $57 after a strong run from $10.60 to over $64 in just several months. The regulatory environment in the U.S. seemed to be warming up and many analysts hurried to issue their BUY…

Read More »

AMN Healthcare Stock to Suffer a 2020-Like Drop

AMN Healthcare Services provides workforce and staffing solutions to healthcare facilities in the U.S. The company is relatively small with a market capitalization of less than $4 billion. However, small companies can make for excellent returns if one happens to identify the winners. And indeed, between late-2011 and early-2020, AMN stock from under $4 to…

Read More »

Zoetis Stock Getting Ahead of Itself, Invites Correction

Based in Parsippany, NJ, Zoetis Inc. is an animal medicine and vaccine developer and manufacturer. The company went public in 2013 and has been enjoying steady growth since. With the stock currently above $160 a share, Zoetis holds a market cap of nearly $80 billion. For a profitable and growing company like Zoetis, a rising…

Read More »

CBOE Stock Looking Good After a Record Year

CBOE Global Markets Inc. is an equities, options and futures exchange operator in the U.S. and Europe. The company traces its roots back to Chicago in 1973, when it practically invented options trading in its present form. CBOE is literally part of the very infrastructure of modern financial markets. So it is not surprising that…

Read More »

Novo Nordisk Bulls Have an Elliott Wave Problem

Novo Nordisk A/S is a Danish pharmaceuticals major with a market cap of over $160 billion. People need their medication even in recessions, so the company’s business wasn’t as affected by the 2020 crisis as most other industries. Novo Nordisk remains a top-notch pharma with consistent profits and revenue and no debt whatsoever. And the…

Read More »

Lockheed ‘s Correction Still Unfolding as Expected

Almost a year and a half ago, in July 2019, we wrote that Lockheed Martin is likely “setting the stage for an unpleasant surprise.” The stock had just reached a new all-time high and was trading at $370 a share. Optimism was in the air and analysts were more bullish than ever. An indeed, fundamentally,…

Read More »

Campari Bulls to Get a Serious Hangover Soon

Campari is an Italian liquor and spirits maker with traditions dating back to 1860. The company’s stock price plunged sharply in March along with the markets in general and then recovered just as quickly to new records by year-end. As shares hover near all-time highs, however, dark clouds appear to be gathering over the spirits…

Read More »

More analyses